Shundi Liu1, Hao Lin1, Yu Chen1, Yuzhen Wang1, Xiaoshan Zhang1, Zheng Xiang2,3, Xiaojun Cai4. 1. School of Pharmaceutical Sciences, Wenzhou Medical University, Chashan Higher Education Campus, Wenzhou, 325035, Zhejiang, China. 2. School of Pharmaceutical Sciences, Wenzhou Medical University, Chashan Higher Education Campus, Wenzhou, 325035, Zhejiang, China. xzh0077@126.com. 3. Medical School, Zhejiang University City College, Hangzhou, 310015, Zhejiang, China. xzh0077@126.com. 4. School of Pharmaceutical Sciences, Wenzhou Medical University, Chashan Higher Education Campus, Wenzhou, 325035, Zhejiang, China. xiaocaixj@163.com.
Abstract
BACKGROUND AND OBJECTIVES: Glabridin is usually used to treat cardiovascular and central nervous system diseases, which is a main bioactive phytoconstituent of licorice root. In this study, our aim was to obtain metabolic profiles of glabridin in rat plasma, urine, bile, and feces after intragastric and intravenous administration. METHODS: By UPLC-QTOF-MS, the metabolites of glabridin were systematically analyzed and identified. An ACQUITY UPLC HSS T3 column (100 × 2.1 mm, 1.8 mm) and the mobile phase containing water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B) via gradient elution was used as the chromatographic condition for separation. An extracted ion chromatogram strategy with multiple prototype/metabolite intermediate templates and 71 typical metabolic reactions was suggested to completely profile the metabolites of glabridin. RESULTS: For the first time, 13 compounds in total were recognized from urine, plasma, bile, and feces of rats with the metabolite profiling strategy. The main metabolic form of glabridin in rats consisted of the prototype, hydroxylation, glucuronide conjugation, decarbonylation, and tert-butyl to alcohol metabolites. CONCLUSIONS: The results not only indicated a comprehensive study on the probable metabolic pathways of glabridin in vivo, but also provided useful data and information for future pharmacological studies of glabridin.
BACKGROUND AND OBJECTIVES: Glabridin is usually used to treat cardiovascular and central nervous system diseases, which is a main bioactive phytoconstituent of licorice root. In this study, our aim was to obtain metabolic profiles of glabridin in rat plasma, urine, bile, and feces after intragastric and intravenous administration. METHODS: By UPLC-QTOF-MS, the metabolites of glabridin were systematically analyzed and identified. An ACQUITY UPLC HSS T3 column (100 × 2.1 mm, 1.8 mm) and the mobile phase containing water with 0.1% formic acid (A) and acetonitrile with 0.1% formic acid (B) via gradient elution was used as the chromatographic condition for separation. An extracted ion chromatogram strategy with multiple prototype/metabolite intermediate templates and 71 typical metabolic reactions was suggested to completely profile the metabolites of glabridin. RESULTS: For the first time, 13 compounds in total were recognized from urine, plasma, bile, and feces of rats with the metabolite profiling strategy. The main metabolic form of glabridin in rats consisted of the prototype, hydroxylation, glucuronide conjugation, decarbonylation, and tert-butyl to alcohol metabolites. CONCLUSIONS: The results not only indicated a comprehensive study on the probable metabolic pathways of glabridin in vivo, but also provided useful data and information for future pharmacological studies of glabridin.
Authors: Eun Mi Choi; Kwang Sik Suh; Woon-Won Jung; So Young Park; Sang Ouk Chin; Sang Youl Rhee; Youngmi Kim Pak; Suk Chon Journal: J Appl Toxicol Date: 2018-07-26 Impact factor: 3.446
Authors: Moo Rim Kang; Ki Hwan Park; Soo Jin Oh; Jieun Yun; Chang Woo Lee; Myeong Youl Lee; Sang-Bae Han; Jong Soon Kang Journal: Int Immunopharmacol Date: 2015-10-29 Impact factor: 4.932